-
Tytuł:
-
Anti-ATP synthase autoantibodies from patients with Alzheimer's disease reduce extracellular HDL level.
-
Autorzy:
-
Vacirca D
Barbati C
Scazzocchio B
Masella R
Rosano G
Malorni W
Ortona E
Vacirca, Davide
Barbati, Cristiana
Scazzocchio, Beatrice
Masella, Roberta
Rosano, Giuseppe
Malorni, Walter
Ortona, Elena
-
Temat:
-
ADENOSINE triphosphate metabolism
NUCLEOTIDE metabolism
ADENOSINE triphosphatase
ALZHEIMER'S disease
APOPTOSIS
AUTOANTIBODIES
CELLS
ENZYME inhibitors
EXTRACELLULAR space
HIGH density lipoproteins
IMMUNITY
STILBENE
FLUORESCENT dyes
CHEMICAL inhibitors
PHARMACODYNAMICS
-
Źródło:
-
Journal of Alzheimer's Disease; 2011, Vol. 23 Issue 1, p441-445, 5p
-
Aside from being an integral protein involved in the synthesis and hydrolysis of ATP, Ecto-F1-ATPase plays a role in cholesterol homeostasis. We demonstrated the presence of autoantibodies to ecto-F1-ATPase (ASabs) in sera and cerebrospinal fluids from patients with Alzheimer's disease (AD). Herein we show that ASabs, unlike irrelevant antibodies, can increase cellular uptake of HDL, a risk factor for the development of AD, via a mechanism involving the prototypical function of ecto-F1-ATPase: the generation of ADP due to the hydrolysis of ATP. Piceatannol, a specific inhibitor ecto-F1-ATPase, completely hindered these effects. We hypothesize that ASabs could exert a pathogenetic role in AD. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Alzheimer's Disease is the property of IOS Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)